https://medaffairs.bluerocktx.com/resources/ 2026-07-18T21:28:40+00:00 https://medaffairs.bluerocktx.com/resource/phase-i-trial-of-hes-cell-derived-dopaminergic-neurons-for-parkinsons-disease/ 2026-07-18T21:21:03+00:00 https://medaffairs.bluerocktx.com/resource/expdite-2-a-phase-3-randomized-sham-controlled-double-blind-trial-to-evaluate-bemdaneprocel-3/ 2026-07-18T21:22:35+00:00 https://medaffairs.bluerocktx.com/resource/continued-evaluation-of-safety-motor-and-non-motor-outcomes-in-participants-with-parkinsons-disease-through-3-years-after-bemdaneprocel-administration/ 2026-07-18T21:23:09+00:00 https://medaffairs.bluerocktx.com/resource/continued-evaluation-of-bemdaneprocel-following-a-phase-1-study-for-parkinsons-disease-outcomes-through-3-years/ 2026-07-18T21:24:29+00:00 https://medaffairs.bluerocktx.com/resource/motor-and-non-motor-outcomes-of-bemdaneprocel-in-people-with-parkinsons-disease-results-up-to-24-months-from-a-phase-1-study/ 2026-07-18T21:25:33+00:00 https://medaffairs.bluerocktx.com/resource/safety-and-tolerability-of-bemdaneprocel-in-people-with-parkinsons-disease-results-up-to-24-months-from-a-phase-1-study-4/ 2026-07-18T21:26:18+00:00 https://medaffairs.bluerocktx.com/resource/safety-tolerability-and-clinical-assessment-of-bemdaneprocel-for-parkinsons-disease-results-up-to-18-months-from-a-phase-1-study/ 2026-07-18T21:26:52+00:00 https://medaffairs.bluerocktx.com/resource/imaging-outcomes-of-a-dopaminergic-neuronal-cell-therapy-for-parkinsons-disease-18-month-results/ 2026-07-18T21:27:31+00:00 https://medaffairs.bluerocktx.com/resource/non-motor-effects-of-bemdaneprocel-for-parkinsons-disease-results-up-to-18-months-from-a-phase-1-study/ 2026-07-18T21:28:03+00:00 https://medaffairs.bluerocktx.com/resource/dopaminergic-neuronal-cell-therapy-for-parkinsons-disease-results-from-a-phase-1-study-of-bemdaneprocel/ 2026-07-18T21:28:40+00:00